Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2014; 60(1): 84-90


Serum levels of endothelial monocyte-activating polypeptide-II in type 2 diabetes mellitus

Mohyl'nyts'ka LA.

    Regional Hospital, Khmelnitsky, Ukraine
DOI: https://doi.org/10.15407/fz60.01.084

Abstract

Endothelial dysfunction is implicated in the pathogenesis of macrovascular complications of diabetes and atherosclerosis. Endothelial monocyte-activating polypeptide-II (EMAPII) is a multifunctional polypeptide with proinflammatory and antiangiogenic activity. The aim of this study was to investigate the serum level of EMAP-II in obese and nonobese patients with type 2 diabetes. We found an increase of serum level of EMAP-II in obese diabetic patients compared to obese subjects without diabetes. Similar alterations were observed also in non-obese diabetic patients compared to control subjects. Moreover, it was significant elevation of serum EMAP-II in obese patients without diabetes compared to control subjects. In obese and non-obese patients with diabetes it was a significant correlation between HbAc1, blood glucose, body mass index and levels of EMAP-II, total cholesterol, LDL, HDL, triglycerides and EMAP-II. In obese non-diabetic patients it was significant correlation between BMI, triglycerides, total cholesterol and EMAP-II. The revealed change of EMAP-II serum level reflects an endothelial dysfunction in patients with type 2 diabetes. Hyperglycemia, dyslipidemia and obesity appear to be significant factors contributing to elevation of EMAP-II level

Keywords: EMAP-II, diabetes, endothelial dysfunction.

References

  1. Awasthi N., Schwarz M.A., Verma V., Cappiello C.,Schwarz R.E. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest. 2009; 89(1): 38-46. CrossRef PubMed
  2.  
  3. Fajardo L.F., Kwan H.H., Kowalski J., Prionas S.D., Allison A.C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992; 140: 539-544. PubMed PubMedCentral
  4.  
  5. Kao J., Houck K., Fan Y., Haehnel I., Libutti S.K., Kayton. L., Grikscheit T., Chabot J., Nowygrod R., Greenberg S., et al. Characterization of a novel tumor-derived cytokine. Endothelial monocyte activating polypeptide II. J Biol Chem. 1994; 269(40):25106-19. PubMed
  6.  
  7. Kao J., Fan Y.G., Haehnel I., Brett J., Greenberg S, Clauss M, Kayton M, Houck K, Kisiel W, Seljelid R., et al. A peptide derived from the amino terminus of endothelial-monocyteactivating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem1994; 269(13):9774-82. PubMed
  8.  
  9. Keezer S.M., Ivie S.E., Krutzsch H.C., Tandle A., Libutti S.K., Roberts D.D. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res. 2003; 63(19):6405-12. PubMed
  10.  
  11. Nuhrenberg T.G., Langwieser N., Schwarz J.B., Hou Y., Frank P., Sorge F., Matschurat S., Seidl S., Kastrati A., Schomig A., Clauss M.A., Zohlnhofer D. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. Cardiovasc Res. 2008; 77(3); 580-589. CrossRef PubMed
  12.  
  13. Park S.G., Kang Y.S., Ahn Y.H., Lee S.H., Kim K.R., Kim K.W., Koh G.Y., Ko Y.G., Kim S. Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, inangiogenesis. J Biol Chem. 2002; 277(47):45243-48. CrossRef PubMed
  14.  
  15. Reznikov A.G., Chaykovskaya L.V., Polyakova L.I.,Kornelyuk A.I., Grygorenko V.N. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts. Exp Oncol. 2011; 33(4):231-34. PubMed
  16.  
  17. Reznikov A.G., Chaykovskaya L.V., Polyakova L.I., Kornelyuk A.I. Antitumor effect of endothelial monocyte- activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. Exp Oncol. 2007; 29(4):267-71. PubMed
  18.  
  19. Schror K. Blood vessel wall interactions in diabetes. Diabetes. 1997; 46(2):115-8. CrossRef  
  20. Schwarz M.A., Zheng H., Liu J., Corbett S., Schwarz R.E. Endothelialmonocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res. 2005; 311(2):229-239. CrossRef PubMed
  21.  
  22. Tandle A.T., Calvani M., Uranchimeg B., Zahavi D., Melillo G., Libutti S.K. Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1-alpha through interaction with PSMA7, a component of the proteasome. Exp Cell Res. 2009; 315(11):1850-59. CrossRef PubMed
  23.  
  24. Thompson J.L., Ryan J.A., Barr M.L., Franc B., Starnes V.A., Schwarz M.A. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004; 116(1):156-64. CrossRef PubMed
  25.  
  26. Tooke J.E. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications. 2000; 14(4):197-200. CrossRef  
  27. Tsai B.M., Wang M., Clauss M., Sun P., Meldrum D.R. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. Am J Physiol Regul Integr Comp Physiol. 2004; 287(4):767-71. CrossRef PubMed
  28.  
  29. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. Eur Heart J. 1997; 18(E):19-29.
  30.  
  31. Van Horssen R., Eggermont A.M., ten Hagen T.L. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006; 17(5):339-48. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.